Carly C Barron
Overview
Explore the profile of Carly C Barron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mesci A, Barron C, Mete O
Mayo Clin Proc
. 2024 Oct;
99(12):1867-1868.
PMID: 39453331
No abstract available.
2.
Barron C, Pittman T, Xu W, Madunic M, Agelastos N, Goldstein D, et al.
J Natl Compr Canc Netw
. 2024 Jun;
22(5).
PMID: 38917848
Background: The impact of COVID-19 pandemic-related disruptions on cancer services is emerging. We evaluated the impact of the first 2 years of the pandemic on new patient consultations for all...
3.
Megid T, Sharma D, Baskurt Z, Xiaolu Ma L, Wang X, Barron C, et al.
Oncologist
. 2024 Mar;
29(4):316-323.
PMID: 38431782
Background: Patient-reported outcomes measures (PROM) are self-reflections of an individual's physical functioning and emotional well-being. The Edmonton Symptom Assessment Scale (ESAS) is a simple and validated PRO tool of 10...
4.
Megid T, Baskurt Z, Ma L, Barron C, Farooq A, Saltiel M, et al.
J Neurooncol
. 2024 Feb;
167(1):111-122.
PMID: 38372902
Background: Brain metastasis (BrM) and Leptomeningeal Carcinomatosis (LMC) are uncommon complications in gastroesophageal carcinoma (GEC) patients. These patients have a poor prognosis and are challenging to treat. We described the...
5.
Barron C, Stefanova I, Cha Y, Elsolh K, Zereshkian A, Gaafour N, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37536939
Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents....
6.
Barron C, Wang X, Elimova E
Thorac Surg Clin
. 2023 Apr;
33(2):197-208.
PMID: 37045489
Neoadjuvant strategies with multimodal therapy including chemotherapy and radiation are the standard of care in locally advanced esophageal cancer. The role of immunotherapy in the perioperative management of esophageal cancer...
7.
Cirne F, Zhou S, Kappel C, El-Kadi A, Barron C, Ellis P, et al.
Lung Cancer
. 2021 Sep;
161:9-17.
PMID: 34492553
Introduction: Anaplastic Lymphoma Kinase (ALK) inhibitors have revolutionized the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC), improving progression-free survival. Bradycardia is a potential adverse effect of these agents....
8.
Leong D, Cosman T, Alhussein M, Tyagi N, Karampatos S, Barron C, et al.
JACC CardioOncol
. 2021 Aug;
1(1):1-10.
PMID: 34396157
Objectives: This study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor-positive breast cancer who developed mild cardiotoxicity. Background: Cardiotoxicity is the most...
9.
Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation
Gurusamy K, Moher D, Loizidou M, Ahmed I, Avey M, Barron C, et al.
PeerJ
. 2021 Feb;
9:e10673.
PMID: 33569250
Background: Only a small proportion of preclinical research (research performed in animal models prior to clinical trials in humans) translates into clinical benefit in humans. Possible reasons for the lack...
10.
McGinn R, Fergusson D, Stewart D, Kristof A, Barron C, Thebaud B, et al.
Crit Care Med
. 2020 Dec;
49(2):311-323.
PMID: 33332817
Objectives: In many jurisdictions, ethical concerns require surrogate humane endpoints to replace death in small animal models of acute lung injury. Heterogenous selection and reporting of surrogate endpoints render interpretation...